Kyse-150人食管鳞癌细胞

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1091

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameKYSE-150
SynonymsKYSE 150; KYSE150; Kyse150; KY150
AccessionBTCC-1091
Resource Identification InitiativeTo cite this cell line use: KYSE-150 (BTCC-1091)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: 13.7 hours (PubMed=1728357); 23 hours (PubMed=25984343);<25 hours (Note=Less when serum amount is increased) (DSMZ=ACC-375).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP).
Genome ancestrySource: PubMed=30894373

Origin% genome


African0.41
Native American0
East Asian, North79.69
East Asian, South18.82
South Asian0
European, North0
European, South1.08
DiseaseEsophageal squamous cell carcinoma (NCIt: C4024)
Squamous cell carcinoma of the esophagus (ORDO: Orphanet_99977)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:

CVCL_C3LZ (KYSE-150R)
Sex of cellFemale
Age at sampling49Y
CategoryCancer cell line
STR profileSource(s): Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12,13
D2S133825
D3S135815,16
D5S81812,13
D7S82010,11
D8S117910,15 (PubMed=25877200)
15 (DSMZ)
D13S3178,11
D16S5399,11
D18S5114
D19S43315
D21S1130,31
FGA21,24
Penta D10
Penta E12,18
TH017,9
TPOX8
vWA16,17

Run an STR similarity search on this cell line
Publications

PubMed=1728357; DOI=10.1002/1097-0142(19920115)69:2<277::aid-cncr2820690202>3.0.CO;2-C
Shimada Y., Imamura M., Wagata T., Yamaguchi N., Tobe T.
Characterization of 21 newly established esophageal cancer cell lines.
Cancer 69:277-284(1992)

PubMed=7913084; DOI=10.1002/ijc.2910580224
Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H., Fukumoto M.
Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines.
Int. J. Cancer 58:291-297(1994)

PubMed=9033652; DOI=10.1002/(SICI)1097-0215(19970207)70:4<437::aid-ijc11>3.0.CO;2-C
Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.
Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines.
Int. J. Cancer 70:437-442(1997)

PubMed=11092977; DOI=10.1111/j.1349-7006.2000.tb00895.x
Pimkhaokham A., Shimada Y., Fukuda Y., Kurihara N., Imoto I., Yang Z.-Q., Imamura M., Nakamura Y., Amagasa T., Inazawa J.
Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon.
Jpn. J. Cancer Res. 91:1126-1133(2000)

PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172
Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K., Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.
Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma.
Cancer Res. 64:3741-3747(2004)

PubMed=16045545; DOI=10.1111/j.0959-9673.2005.00431.x
Ban S., Michikawa Y., Ishikawa K.-I., Sagara M., Watanabe K., Shimada Y., Inazawa J., Imai T.
Radiation sensitivities of 31 human oesophageal squamous cell carcinoma cell lines.
Int. J. Exp. Pathol. 86:231-240(2005)

PubMed=16832412; DOI=10.1038/sj.bjc.6603255
Tsunoda S., Okumura T., Ito T., Mori Y., Soma T., Watanabe G., Kaganoi J.-I., Itami A., Sakai Y., Shimada Y.
Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma.
Br. J. Cancer 95:322-330(2006)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21191746; DOI=10.1007/s11684-010-0260-x
Ji J.-F., Wu K., Wu M., Zhan Q.-M.
p53 functional activation is independent of its genotype in five esophageal squamous cell carcinoma cell lines.
Front. Med. China 4:412-418(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36090890; DOI=10.1155/2022/5632744
Gu Z.-L., Zhu W.-G., Wang W.-W., Xu Y.-Y., Jiang L., Huang J.-S., Huang J.
Anlotinib inhibits tumor angiogenesis and promotes the anticancer effect of radiotherapy on esophageal cancer through inhibiting EphA2.
J. Oncol. 2022:5632744.1-5632744.11(2022)

Cross-references
Cell line databases/resourcesCLO; CLO_0007129
CCRID; 3101HUMTCHu236
Cell_Model_Passport; SIDM01031
CGH-DB; 278-1
CGH-DB; 9227-4
Cosmic-CLP; 907317
DepMap; ACH-000855
DSMZCellDive; ACC-375
LINCS_HMS; 50025
LINCS_LDP; LCL-1548
Anatomy/cell type resourcesBTO; BTO:0002427
Biological sample resourcesBioSample; SAMN03471047
BioSample; SAMN10988383
Cell line collections (Providers)CLS; 305087
DSMZ; ACC-375
JCRB; JCRB1095 - Discontinued
Chemistry resourcesChEMBL-Cells; CHEMBL3307840
ChEMBL-Targets; CHEMBL613998
GDSC; 907317
PharmacoDB; KYSE150_802_2019
PubChem_Cell_line; CVCL_1348
Encyclopedic resourcesWikidata; Q54900805
Experimental variables resourcesEFO; EFO_0006627

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部